<SEC-DOCUMENT>0001193125-26-182352.txt : 20260427
<SEC-HEADER>0001193125-26-182352.hdr.sgml : 20260427
<ACCEPTANCE-DATETIME>20260427170117
ACCESSION NUMBER:		0001193125-26-182352
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20260427
DATE AS OF CHANGE:		20260427

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Ovid Therapeutics Inc.
		CENTRAL INDEX KEY:			0001636651
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				465270895
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-295218
		FILM NUMBER:		26901883

	BUSINESS ADDRESS:	
		STREET 1:		441 NINTH AVENUE, 14TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10001
		BUSINESS PHONE:		212-776-4381

	MAIL ADDRESS:	
		STREET 1:		441 NINTH AVENUE, 14TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10001
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>d108102d424b3.htm
<DESCRIPTION>424B3
<TEXT>
<HTML><HEAD>
<TITLE>424B3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Filed Pursuant to Rule 424(b)(3)<BR>Registration No. 333-295218 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g108102g02a01.jpg" ALT="LOGO" STYLE="width:2.50261in;height:0.800833in;">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>29,856,031 Shares of Common Stock </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus relates to the offer and resale from time to time by the selling stockholders identified herein, together with any additional
selling stockholders listed in a prospectus supplement (together with any of such stockholders&#8217; donees, pledgees, assignees, transferees, distributees and
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">successors-in-interest),</FONT></FONT> of up to an aggregate of 29,856,031 shares of our common stock, par value $0.001 per share, issued by us pursuant to a private placement that
closed on March&nbsp;19, 2026, consisting of (i) 19,154,321 shares of our common stock and (ii) 10,701,710 shares of our common stock issuable upon the exercise of outstanding <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants (the <FONT
STYLE="white-space:nowrap">&#8220;Pre-Funded</FONT> Warrants&#8221;) to purchase shares of our common stock. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are filing this
Registration Statement on Form <FONT STYLE="white-space:nowrap">S-3,</FONT> of which this prospectus forms a part, to fulfill our contractual obligations with the selling stockholders to provide for the resale by the selling stockholders of the
shares of our common stock described in this prospectus. The registration of the shares to which this prospectus relates does not require the selling stockholders to sell any of their shares, including any shares of common stock issuable upon the
exercise of <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are not offering any shares of common stock pursuant to this
prospectus and will not receive any proceeds from the sale or other disposition of shares of common stock offered by this prospectus by the selling stockholders; however, we will receive nominal proceeds from any cash exercise of <FONT
STYLE="white-space:nowrap">the&nbsp;Pre-Funded&nbsp;Warrants.</FONT> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The selling stockholders may offer and sell or otherwise dispose of
the shares of our common stock described in this prospectus from time to time through public or private transactions at prevailing market prices, at prices related to prevailing market prices or at privately negotiated prices. The selling
stockholders will bear all underwriting fees, commissions and discounts, if any, attributable to the sales of shares and any transfer taxes. We will bear all other costs, expenses and fees in connection with the registration of the shares. See
&#8220;Plan of Distribution&#8221; for more information about how the selling stockholders may sell or dispose of their shares of our common stock. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock is listed on The Nasdaq Capital Market under the trading symbol &#8220;OVID.&#8221; On April&nbsp;24, 2026, the last reported
sale price of the common stock was $2.60 per share. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:12pt; font-family:Times New Roman"><B>Investing in our common stock involves a high degree of risk. You should review carefully the risks and uncertainties described under the
heading &#8220;<A HREF="#rom108102_3">Risk Factors</A>&#8221; on page 4 of this prospectus, and under similar headings in the other documents that are incorporated by reference into this prospectus. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or
determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of this prospectus is April 24, 2026.<BR><BR><BR><BR> </B></P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom108102_1">ABOUT THIS PROSPECTUS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">ii</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom108102_2">PROSPECTUS SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom108102_3">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom108102_4">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom108102_5">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom108102_6">SELLING STOCKHOLDERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom108102_7">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom108102_8">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom108102_9">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom108102_10">WHERE YOU CAN FIND ADDITIONAL INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom108102_11">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom108102_1"></A>ABOUT THIS PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus is a part of a registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> that we filed with the Securities
and Exchange Commission (the &#8220;SEC&#8221;) utilizing a &#8220;shelf&#8221; registration process under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). Under this shelf registration process, the selling stockholders may
from time to time sell the shares of common stock described in this prospectus in one or more offerings or otherwise as described under &#8220;Plan of Distribution.&#8221; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither we nor the selling stockholders have authorized anyone to provide you with any information other than that contained in, or
incorporated by reference into, this prospectus. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. This prospectus is an offer to sell only the shares of our common
stock offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. You should not assume that the information contained in or incorporated by reference in this prospectus is accurate as of any date other than their
respective dates. Our business, financial condition, results of operations and prospects may have changed since those dates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This
prospectus contains summaries of certain provisions contained in some of the documents described herein, but reference is made to the actual documents for complete information. All of the summaries are qualified in their entirety by the actual
documents. Copies of some of the documents referred to herein have been filed, will be filed or will be incorporated by reference as exhibits to the registration statement of which this prospectus is a part, and you may obtain copies of those
documents as described below under the section titled &#8220;Where You Can Find Additional Information.&#8221; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless the context
indicates otherwise, as used in this prospectus, the terms &#8220;Ovid,&#8221; &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to Ovid Therapeutics Inc. </P>
<P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom108102_2"></A>PROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>This summary highlights selected information contained elsewhere in this prospectus or incorporated by reference in this prospectus, and
does not contain all of the information that you need to consider in making your investment decision. You should carefully read the entire prospectus, including the risks of investing in our securities discussed under the heading &#8220;Risk
Factors&#8221; contained in this prospectus and under similar headings in the other documents that are incorporated by reference into this prospectus. You should also carefully read the information incorporated by reference into this prospectus,
including our financial statements, and the exhibits to the registration statement of which this prospectus is a part. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a biopharmaceutical company dedicated to developing small molecule medicines for brain disorders with significant unmet need. Our
approach to achieve this goal is scientifically driven, patient-focused, and coupled with an integrated and disciplined approach to research, clinical development and business development. Our team has significant experience with and understanding
of epilepsies and other neurological conditions, and we continue to gain insight into the ways the different molecular mechanisms and pathways underlying these disorders impact the symptoms patients experience. We have developed a differentiated
pipeline of drug candidates containing novel mechanisms of action to target seizures and believe we are the only company that holds a portfolio of direct activators of potassium-chloride cotransporter 2. One of our programs is in clinical trials in
humans, and a second is expected to begin a clinical trial in the first half of 2026. We are initially pursuing therapeutic drug candidates for the potential treatment of drug-resistant focal onset seizures, developmental and epileptic
encephalopathies, including tuberous sclerosis complex seizures and infantile spasms, psychosis associated with Parkinson&#8217;s disease and Lewy body dementia, and schizophrenia. If successfully developed and marketed to treat these conditions, we
intend to explore these drug candidates for broader neurologic indications. Our cohesive focus in brain disorders with significant unmet need reinforces our belief that we can develop and produce multiple novel medicines, scale our infrastructure,
positively impact patients&#8217; lives and create long-term stockholder value. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Private Placement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&nbsp;17, 2026, we entered into a securities purchase agreement with the purchasers named therein (the &#8220;Investors&#8221;),
pursuant to which we agreed to issue and sell in a private placement 29,856,031 shares of common stock, consisting of (i) 19,154,321 shares of our common stock and <FONT STYLE="white-space:nowrap">(ii)&nbsp;Pre-Funded</FONT> Warrants to purchase up
to 10,701,710 shares of our common stock to the Investors in a private placement (the &#8220;Private Placement&#8221;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each share of
common stock was sold at a purchase price of $2.01 per share of common stock to the Investors, and each <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant was sold at a purchase price of $2.009 per
<FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant to the Investors. Each <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant has an exercise price of $0.001 per share and became exercisable immediately upon the Original Issue Date
(as defined in the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant) until the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant is exercised in full. We received gross proceeds of approximately $60.0&nbsp;million from the Private
Placement, before placement agent fees and offering expenses payable by us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&nbsp;17, 2026, we also entered into a registration
rights agreement (the &#8220;Registration Rights Agreement&#8221;) with the Investors, pursuant to which we agreed to register for resale the common stock described in this prospectus. Under the Registration Rights Agreement, we are required to
prepare and file a registration statement with the SEC no later than the 30<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> business day following the closing of the Private Placement and to use reasonable best efforts to have the
registration statement declared effective within 60 calendar days after the initial filing date of such registration statement, subject to certain exceptions and specified penalties if timely effectiveness is not achieved and maintained. The
registration statement of which this prospectus forms a part is being filed to satisfy the requirements of the Registration Rights Agreement. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are only registering pursuant to the registration statement of which this prospectus
forms a part (i)&nbsp;the shares of common stock and (ii)&nbsp;the shares of common stock issuable upon exercise of the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants, that were issued and sold in the Private Placement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The Nasdaq Capital Market Listing </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
common stock is listed on The Nasdaq Capital Market under the symbol &#8220;OVID.&#8221; We do not intend to list the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants on any national securities exchange. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We were
incorporated in Delaware in April 2014. Our principal executive offices are located at 441 Ninth Avenue, 14th Floor, New York, New York 10001 and our telephone number is (646) <FONT STYLE="white-space:nowrap">661-7661.</FONT> Our common stock is
listed on Nasdaq under the symbol &#8220;OVID.&#8221; Our corporate website address is www.ovidrx.com. Information contained on or accessible through our website is not incorporated by reference into this prospectus, and you should not consider any
information contained on, or that can be accessed through, our website as part of this prospectus. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>THE OFFERING </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Common stock offered by the selling stockholders</B> </P></TD>
<TD>29,856,031 shares of common stock, consisting of (i) 19,154,321 shares of our common stock and (ii) 10,701,710 shares of our common stock issuable upon the exercise of the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants.
</TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Use of proceeds</B> </P></TD>
<TD>We will not receive any proceeds from the sale of shares of common stock offered by this prospectus by the selling stockholders; however, we will receive nominal proceeds from any cash exercise of
<FONT STYLE="white-space:nowrap">the&nbsp;Pre-Funded&nbsp;Warrants.</FONT> </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Risk factors</B> </P></TD>
<TD>An investment in our common stock involves a high degree of risk. See the information contained in or incorporated by reference in the section titled &#8220;Risk Factors&#8221; and under similar headings in the other documents that are
incorporated by reference herein, as well as the other information included in or incorporated by reference in this prospectus. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Nasdaq Capital Market symbol</B> </P></TD>
<TD>&#8220;OVID&#8221; </TD></TR></TABLE> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom108102_3"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Investing in our common stock involves a high degree of risk. Before deciding whether to invest in our common stock, you should consider
carefully the risks and uncertainties described under the heading &#8220;Risk Factors&#8221; contained in our most recent annual report on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> as updated by our subsequent quarterly reports on Form <FONT
STYLE="white-space:nowrap">10-Q</FONT> and other filings we make with the SEC, which are incorporated by reference into this prospectus in their entirety, together with other information in this prospectus and the documents incorporated by
reference. The risks described in these documents are not the only ones we face, but those that we consider to be material. There may be other unknown or unpredictable economic, business, competitive, regulatory or other factors that could have
material adverse effects on our future results. Past financial performance may not be a reliable indicator of future performance, and historical trends should not be used to anticipate results or trends in future periods. If any of these risks
actually occur, our business, financial condition, results of operations or cash flow could be harmed. This could cause the trading price of our common stock to decline, resulting in a loss of all or part of your investment. Please also read
carefully the section below titled &#8220;Special Note Regarding Forward-Looking Statements.&#8221; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom108102_4"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus and any applicable prospectus supplement or free writing prospectus, including the documents that we incorporate by reference
herein and therein, contain &#8220;forward-looking statements&#8221; within the meaning of Section&nbsp;27A of the Securities Act and Section&nbsp;21E of the Exchange Act. These statements relate to future events or to our future operating or
financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or
implied by such forward-looking statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In some cases, you can identify forward-looking statements by terms such as
&#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;expects,&#8221; &#8220;plans,&#8221; &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;projects,&#8221;
&#8220;predicts,&#8221; &#8220;potential&#8221; and similar expressions intended to identify forward-looking statements. These statements reflect our current views with respect to future events, are based on assumptions and are subject to risks and
uncertainties. As such, our actual results may differ significantly from those expressed in any forward-looking statements. Given these uncertainties, you should not place undue reliance on these forward-looking statements. In addition, statements
indicating that &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date they were made, and while we believe such
information formed a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available
relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
discuss many of these risks in greater detail in the &#8220;Risk Factors,&#8221; &#8220;Business&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; sections incorporated by reference
from our most recent Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> and in our Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarterly periods ended subsequent to our filing of such Annual Report
on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> as well as any amendments thereto reflected in subsequent filings with the SEC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Also, these forward-looking statements represent our estimates and assumptions only as of the date of the document containing the applicable
statement. Unless required by law, we undertake no obligation to update or revise any forward-looking statements to reflect new information or future events or developments. Thus, you should not assume that our silence over time means that actual
events are bearing out as expressed or implied in such forward-looking statements. You should read this prospectus, any applicable prospectus supplement, together with the documents that we have filed with the SEC that are incorporated by reference
and any free writing prospectus we have authorized for use in connection with this offering, completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of the forward-looking
statements in the foregoing documents by these cautionary statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom108102_5"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All the shares of our common stock to be sold pursuant to this prospectus will be sold by the selling stockholders. We will not receive any
proceeds from the sale of shares of common stock offered by this prospectus by the selling stockholders; however, we will receive nominal proceeds from any cash exercise of <FONT STYLE="white-space:nowrap">the&nbsp;Pre-Funded&nbsp;Warrants.</FONT>
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom108102_6"></A>SELLING STOCKHOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus covers the resale or other disposition from time to time by selling stockholders identified in the table below of up to an
aggregate of 29,856,031 shares of common stock, consisting of (i) 19,154,321 shares of our common stock issued in the Private Placement and (ii) 10,701,710 shares of our common stock issuable upon the exercise of the
<FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants issued in the Private Placement. For additional information regarding the issuance of the common stock and <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants in connection with the
Private Placement, see the section &#8220;Prospectus Summary&#8212;Private Placement&#8221; above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As used in this prospectus, the term
&#8220;selling stockholders&#8221; or &#8220;selling stockholder&#8221; includes the selling stockholders listed in the table below, together with any additional selling stockholders listed in a subsequent amendment to this prospectus, and their
donees, pledgees, assignees, transferees, distributees and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">successors-in-interest</FONT></FONT> that receive shares in any <FONT STYLE="white-space:nowrap">non-sale</FONT> transfer
after the date of this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except for their participation in the Private Placement, the selling stockholders do not have, and
within the past three years have not had, any position, office or other material relationship with us, except as herein described. Prior to the Private Placement, entities affiliated with Janus Henderson Investors, RA Capital Healthcare Fund, L.P.,
Point72 Associates, LLC, Affinity Healthcare Fund, LP and entities affiliated with ADAR1 Capital Management, LLC were beneficial owners of more than 5% of our common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are registering the offer and sale of the shares of common stock to satisfy certain registration obligations that we granted the selling
stockholders in connection with the Private Placement. Under the Registration Rights Agreement, we are required to prepare and file a registration statement with the SEC no later than the Filing Deadline (as defined in the Registration Rights
Agreement) and to use reasonable best efforts to have the registration statement declared effective within 60 days after the filing date of such registration statement, subject to certain exceptions and specified penalties if timely effectiveness is
not achieved and maintained. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The table below lists the selling stockholders and other information regarding the beneficial ownership of
the shares of common stock by each of the selling stockholders as of April&nbsp;17, 2026. This information has been obtained from the selling stockholders or in Schedules 13G or 13D and other public documents filed with the SEC, and upon information
in our possession regarding the securities issued in the Private Placement. Beneficial ownership is determined in accordance with the rules of the SEC and includes voting or investment power with respect to our common stock. Except as indicated by
the footnotes below, we believe, based on the information furnished to us, that each selling stockholder named in the table below has sole voting and investment power with respect to all shares of common stock that they beneficially own, subject to
applicable community property laws. The first column lists the number of shares of common stock beneficially owned by each selling stockholder, based on its ownership of shares of common stock and <FONT STYLE="white-space:nowrap">Pre-Funded</FONT>
Warrants as of April&nbsp;17, 2026. The percentages of shares owned after the offering in the fourth column is based on 173,037,131 shares of common stock outstanding as of April&nbsp;17, 2026, plus, for each selling stockholder, the shares of
common stock issuable upon exercise of the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants. The second column assumes the sale of all of the shares offered by the selling stockholders pursuant to this prospectus. The registration of the
shares does not necessarily mean that the selling stockholders will sell all or any portion of the shares covered by this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
accordance with the terms of the Registration Rights Agreement, this prospectus covers the resale of the maximum number of shares of common stock issuable upon exercise of the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>After Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name of Selling Stockholder</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;Shares<BR>Beneficially<BR>Owned<BR>Before&nbsp;Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Shares&nbsp;Being<BR>Offered</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Shares<BR>Beneficially<BR>Owned</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage&nbsp;of<BR>Shares<BR>Beneficially<BR>Owned</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SILV Fund Ltd.<SUP STYLE="font-size:75%; vertical-align:top"> (1) </SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,031,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,313,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,718,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.11</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">RA Capital Healthcare Fund, L.P.<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,448,075</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,986,560</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,635,832</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.99</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mutual Fund Series Trust, on behalf of Eventide Healthcare&nbsp;&amp; Life Sciences Fund<SUP
STYLE="font-size:75%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,954,741</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,736,318</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,218,423</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.11</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Affinity Healthcare Fund, LP<SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,635,484</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,736,318</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,899,166</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.02</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Janus Henderson
Investors<SUP STYLE="font-size:75%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,864,542</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,487,562</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,376,980</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12.72</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Atlas Private Holdings (Cayman)
Ltd.<SUP STYLE="font-size:75%; vertical-align:top">(6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,686,316</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,496,150</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,190,166</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.37</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Coastlands Capital Partners LP<SUP STYLE="font-size:75%; vertical-align:top">(7)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,648,947</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,492,537</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,653,440</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.71</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adage Capital Partners, L.P.<SUP STYLE="font-size:75%; vertical-align:top">(8)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,234,781</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,243,781</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,991,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.35</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ally Bridge MedAlpha Master Fund
L.P.<SUP STYLE="font-size:75%; vertical-align:top">(9)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,136,905</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,243,781</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">893,124</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with ADAR1 Capital Management, LLC <SUP
STYLE="font-size:75%; vertical-align:top">(10)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,543,279</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">995,024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,548,255</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.65</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Point72 Associates, LLC<SUP STYLE="font-size:75%; vertical-align:top">(11)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,209,893</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">125,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,084,893</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.13</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents beneficial ownership of less than 1% </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#8220;Number of Shares Beneficially Owned Before Offering&#8221; consists of (a)&nbsp;10,812,333&nbsp;shares
of common stock, (b)&nbsp;6,219,000&nbsp;shares of common stock issuable upon the exercise of Pre-Funded Warrants from the Private Placement and (c)&nbsp;1,000,000&nbsp;shares of common stock issuable upon the exercise of Series&nbsp;B warrants, in
each case held by SILV Fund Ltd. Sirenia Capital Management LP (&#8220;Sirenia&#8221;) is the investment manager of SILV Fund, Ltd. and as such has investment and voting power with respect to the securities held by SILV Fund, Ltd. Sirenia Capital
Management GP LLC (&#8220;Sirenia GP&#8221;) is the general partner of Sirenia. Alex Silverstein is the managing member of Sirenia GP. Each of SILV Fund, Ltd., Sirenia GP and Mr.&nbsp;Silverstein disclaims beneficial ownership over such securities.
The address for the selling shareholder is 1674 Meridian Avenue, Suite 320, Miami Beach, FL 33139. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#8220;Number of Shares Beneficially Owned Before Offering&#8221; consists of (i) 15,829,800 shares of common
stock and (ii) 1,618,275 shares of common stock issuable upon the exercise of Series B warrants, in each case held by RA Capital Healthcare Fund, L.P. Due to a beneficial ownership blocker, the number of shares beneficially owned before the offering
excludes 8,752,151 shares of common stock issuable upon the exercise of warrants and <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants held by RA Capital Healthcare Fund, L.P. RA Capital Management, L.P. is the investment manager for RA
Capital Healthcare Fund, L.P. The general partner of RA Capital Management, L.P. is RA Capital Management GP, LLC, of which Peter Kolchinsky and Rajeev Shah are the managing members. Each of RA Capital Management, L.P., RA Capital Management GP,
LLC, Mr.&nbsp;Kolchinsky and Mr.&nbsp;Shah may be deemed to have voting and investment power over the shares held by RA Capital Healthcare Fund, L.P. RA Capital Management, L.P., RA Capital Management GP, LLC, Mr.&nbsp;Kolchinsky and Mr.&nbsp;Shah
disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#8220;Number of Shares Beneficially Owned Before Offering&#8221; consists of (a) 11,812,241 shares of common
stock and (b) 2,142,500 shares of common stock issuable upon the exercise of Series B warrants, in each case held by Mutual Fund Series Trust, on behalf of Eventide Healthcare&nbsp;&amp; Life Sciences Fund (the &#8220;Eventide Fund&#8221;). Eventide
Asset Management, LLC (&#8220;Eventide&#8221;) is the investment adviser for the Eventide Fund. Robin C. John is the Chief Executive Officer of Eventide, and Finny Kuruvilla, MD, PhD, is a <FONT STYLE="white-space:nowrap">Co-Chief</FONT> Investment
Officer, Sr. Portfolio Manager and Managing Director of Eventide. Each of Eventide, Mr.&nbsp;John and Dr.&nbsp;Kuruvilla may be deemed to have voting and investment power over the shares held by the Eventide Fund. The Eventide Fund, Mr.&nbsp;John
and Dr.&nbsp;Kuruvilla disclaim beneficial ownership of such shares except to the extent of their pecuniary interest therein. The address of the Eventide Fund is Mutual Fund Series Trust, 4221 North
203<SUP STYLE="font-size:75%; vertical-align:top">rd</SUP> Street, Suite 100, Elkhorn, Nebraska 68022. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#8220;Number of Shares Beneficially Owned Before Offering&#8221; consists of (a) 10,636,318 shares of common
stock, (b) 2,142,500 shares of common stock issuable upon the exercise of Series B warrants and (c) 2,856,666 shares of common stock issuable upon the exercise of <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants, in each case held by
Affinity Healthcare Fund, LP. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#8220;Number of Shares Beneficially Owned Before Offering&#8221; consists of (a)(i) 17,162,264 shares of
common stock and (ii) 4,534,500 shares of common stock issuable upon the exercise of Series B warrants, in each case held by Janus Henderson Biotech Innovation Master Fund Limited, and (b)(i) 3,345,278 shares of common stock and (ii) 822,500 shares
of common stock issuable upon the exercise of Series B warrants, in each case held by Janus Henderson Biotech Innovation Master Fund II Limited. These shares may be deemed to be beneficially owned by Janus Henderson Investors US LLC
(&#8220;Janus&#8221;), an investment adviser registered under the Investment Advisers Act of 1940, who acts as investment adviser for the Janus Funds and has the ability to make decisions with respect to the voting and disposition of the shares
subject to the oversight of the board of directors of the Janus Funds. Under the terms of its management contract with the Janus Funds, Janus has overall responsibility for directing the investments of the Janus Funds in accordance with the Janus
Fund&#8217;s investment objective, policies and limitations. The Janus Funds have one or more portfolio managers appointed by and serving at the pleasure of Janus who makes decisions with respect to the disposition of the shares of Common Stock
offered hereby. The portfolio managers for the Janus Funds are Andrew Acker, Daniel S. Lyons and Agustin Mohedas. Each of Mr.&nbsp;Acker, Mr.&nbsp;Lyons and Mr.&nbsp;Mohedas disclaim any beneficial ownership of these shares. The address of Janus and
each of the Janus Funds is c/o Janus Henderson Investors US LLC, 151 Detroit Street, Denver, CO 80206. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#8220;Number of Shares Beneficially Owned Before Offering&#8221; consists of (a) 4,761,666 shares of common
stock, (b) 1,428,500 shares of common stock issuable upon the exercise of Series B warrants and (c)&nbsp;1,496,150 shares of common stock issuable upon the exercise of <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants, in each case held by
Atlas Private Holdings (Cayman) Ltd. Balyasny Asset Management L.P. is the investment adviser of Atlas Private Holdings (Cayman) Ltd. Dmitry Balyasny, via intermediate entities, manages Balyasny Asset Management L.P. and has voting and investment
control over the securities being registered under this registration statement. The address for Atlas Private Holdings (Cayman) Ltd. and Balyasny Asset Management L.P. is 444 West Lake Street, 50th&nbsp;Floor, Chicago, IL 60606.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#8220;Number of Shares Beneficially Owned Before Offering&#8221; consists of (a)&nbsp;8,360,477 shares of
common stock and (b)&nbsp;288,470 shares of common stock issuable upon the exercise of Series B warrants, in each case held by Coastlands Capital Partners LP (&#8220;Coastlands Capital&#8221;). Due to a beneficial ownership blocker, the number of
shares beneficially owned before the offering excludes 1,497,030 shares of common stock issuable upon the exercise of warrants held by Coastlands Capital. Coastlands Capital LP is the investment adviser to Coastlands Capital and Coastlands Capital
GP LLC (&#8220;Coastlands GP&#8221;) is the general partner of Coastlands Capital. Coastlands Capital LLC (the &#8220;General Partner&#8221;, and together with Coastlands Capital, Coastlands Capital LP and Coastlands GP, the &#8220;Coastlands
Entities&#8221;) is the general partner of Coastlands Capital LP. Matthew D. Perry is the control person of the Coastlands Entities. The Coastlands Entities and Mr.&nbsp;Perry each disclaim membership in a group. The Coastlands Entities and
Mr.&nbsp;Perry also each disclaim beneficial ownership of the shares of Common Stock except to the extent of such entity or person&#8217;s pecuniary interest therein. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#8220;Number of Shares Beneficially Owned Before Offering&#8221; consists of (a) 6,163,781 shares of common
stock and (b) 1,071,000 shares of common stock issuable upon the exercise of Series B warrants, in each case held by Adage Capital Partners, L.P. (&#8220;Adage&#8221;). Bob Atchinson and Phillip Gross are the managing members of Adage Capital
Advisors, L.L.C., which is the managing member of Adage Capital Partners GP, L.L.C., which is the general partner of Adage, and each such person or entity, as the case may be, has shared voting and/or investment power over the securities held by
Adage and may be deemed the beneficial owner of such shares, and each such person or entity, as the case may be, disclaims beneficial ownership of such securities except to the extent of their respective pecuniary interest therein.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#8220;Number of Shares Beneficially Owned Before Offering&#8221; consists of (a)&nbsp;1,244,405 shares of
common stock and (b) 892,500 shares of common stock issuable upon the exercise of Series B warrants, in each case held by Ally Bridge MedAlpha Master Fund L.P. (&#8220;MedAlpha&#8221;). Mr.&nbsp;Fan Yu is the sole shareholder of ABG Management Ltd.,
which is the sole member of Ally Bridge Group (NY) LLC, which manages investments </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
of MedAlpha. As such, each of the foregoing entities and Mr.&nbsp;Fan Yu may be deemed to share beneficial ownership of the shares held by MedAlpha. Each of them disclaims any such beneficial
ownership. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(10)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#8220;Number of Shares Beneficially Owned Before Offering&#8221; consists of (a)(1)&nbsp;6,967,597&nbsp;shares
of common stock and (2) 2,142,500&nbsp;shares of common stock issuable upon the exercise of Series&nbsp;B Warrants, in each case held by ADAR1 Partners LP (&#8220;ADAR1&#8221;), and (b) 433,182&nbsp;shares of Common Stock held by Spearhead Insurance
Solutions IDF, LLC&#8212;Series ADAR1 (&#8220;Spearhead&#8221;) ADAR1 Capital Management, LLC (&#8220;ADAR1 LLC&#8221;), the investment advisor of ADAR1 and the sub-advisor of Spearhead, has voting and investment control of the shares held by ADAR1
and Spearhead. ADAR1 Capital Management GP, LLC (&#8220;ADAR1 GP&#8221;) is the general partner of ADAR1. Daniel Schneebergeris the manager of ADAR1 and ADAR1 GP. The address of ADAR1 is 3503 Wild Cherry Drive, Building 9, Austin, TX 78738. The
address of Spearhead is 3828 Kennett Pike, Suite 202, Greenville, DE 19807. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(11)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#8220;Number of Shares Beneficially Owned Before Offering&#8221; consists of (a) 1,959,893 shares of common
stock and (b) 250,000 shares of common stock issuable upon the exercise of Series B warrants, in each case held by Point72 Associates, LLC. Point72 Asset Management, L.P. maintains investment and voting power with respect to the securities held by
certain investment funds it manages, including Point72 Associates, LLC. Point72 Capital Advisors, Inc. is the general partner of Point72 Asset Management, L.P. Mr.&nbsp;Steven&nbsp;A. Cohen controls each of Point72 Asset Management, L.P. and Point72
Capital Advisors, Inc. By reason of the provisions of Rule <FONT STYLE="white-space:nowrap">13d-3</FONT> of the Exchange Act, each of Point72 Asset Management, L.P., Point72 Capital Advisors, Inc., and Mr.&nbsp;Cohen may be deemed to beneficially
own the securities held by Point72 Associates, LLC that are disclosed herein. Each of Point72 Asset Management, L.P., Point72 Capital Advisors, Inc., and Mr.&nbsp;Cohen disclaims beneficial ownership of any such securities. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom108102_7"></A>PLAN OF DISTRIBUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The selling stockholders, which as used herein includes donees, pledgees, transferees or other <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">successors-in-interest</FONT></FONT> selling shares of common stock or interests therein received after the date of this prospectus from a selling stockholder as a gift, pledge, partnership distribution or other transfer,
may, from time to time, sell, transfer or otherwise dispose of any or all of their shares of common stock or interests therein on any stock exchange, market or trading facility on which the shares are traded or in private transactions. These
dispositions may be at fixed prices, at prevailing market prices at the time of sale, at prices related to the prevailing market price, at varying prices determined at the time of sale, or at negotiated prices. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The selling stockholders may use any one or more of the following methods when disposing of shares or interests therein: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">distributions to members, partners, stockholders or other equity holders of the selling stockholders;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">block trades in which the broker-dealer will attempt to sell the shares as agent, but may position and resell a
portion of the block as principal to facilitate the transaction; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">purchases by a broker-dealer as principal and resale by the broker-dealer for its account; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an exchange distribution in accordance with the rules of the applicable exchange; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">privately negotiated transactions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">short sales and settlement of short sales entered into after the effective date of the registration statement of
which this prospectus is a part; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">through the writing or settlement of options or other hedging transactions, whether through an options exchange
or otherwise; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">broker-dealers may agree with the selling stockholders to sell a specified number of such shares at a stipulated
price per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a combination of any such methods of sale; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other method permitted pursuant to applicable law. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The selling stockholders may, from time to time, pledge or grant a security interest in some or all of the shares of common stock owned by
them and, if they default in the performance of their secured obligations, the pledgees or secured parties may offer and sell the shares of common stock, from time to time, under this prospectus, or under an amendment to this prospectus under Rule
424(b)(3) or other applicable provision of the Securities Act, amending the list of selling stockholders to include the pledgee, transferee or other successors in interest as selling stockholders under this prospectus. The selling stockholders also
may transfer the shares of common stock in other circumstances, in which case the transferees, pledgees or other successors in interest will be the selling stockholders for purposes of this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, a selling stockholder that is an entity may elect to make an <FONT STYLE="white-space:nowrap">in-kind</FONT> distribution of
securities to its members, partners or stockholders pursuant to the registration statement of which this prospectus is a part by delivering a prospectus with a plan of distribution. Such members, partners or stockholders would thereby receive freely
tradeable securities pursuant to the distribution through a registration statement. To the extent a distributee is an affiliate of ours (or to the extent otherwise required by law), we may file a prospectus supplement in order to permit the
distributees to use the prospectus to resell the securities acquired in the distribution. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the sale of our common stock or interests therein, the selling
stockholders may enter into hedging transactions with broker-dealers or other financial institutions, which may in turn engage in short sales of the common stock in the course of hedging the positions they assume. The selling stockholders may also
sell shares of our common stock short and deliver these securities to close out their short positions, or loan or pledge the common stock to broker-dealers that in turn may sell these securities. The selling stockholders may also enter into option
or other transactions with broker-dealers or other financial institutions or the creation of one or more derivative securities which require the delivery to such broker-dealer or other financial institution of shares offered by this prospectus,
which shares such broker-dealer or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The aggregate proceeds to the selling stockholders from the sale of the common stock offered by them will be the purchase price of the common
stock less discounts or commissions, if any. Each of the selling stockholders reserves the right to accept and, together with their agents from time to time, to reject, in whole or in part, any proposed purchase of common stock to be made directly
or through agents. We will not receive any of the proceeds from this offering. Upon any exercise of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants by payment of cash, however, we will receive the exercise price of the <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The selling stockholders also may resell all or a portion of the shares in open
market transactions in reliance upon Rule 144 under the Securities Act, provided that they meet the criteria and conform to the requirements of that rule, or another available exemption from the registration requirements under the Securities Act.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The selling stockholders and any underwriters, broker-dealers or agents that participate in the sale of the common stock or interests
therein may be &#8220;underwriters&#8221; within the meaning of Section&nbsp;2(a)(11) of the Securities Act (it being understood that the selling stockholders shall not be deemed to be underwriters solely as a result of their participation in this
offering). Any discounts, commissions, concessions or profit they earn on any resale of the shares may be underwriting discounts and commissions under the Securities Act. Selling stockholders who are &#8220;underwriters&#8221; within the meaning of
Section&nbsp;2(a)(11) of the Securities Act will be subject to the prospectus delivery requirements of the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent
required, the shares of common stock to be sold, the names of the selling stockholders, the respective purchase prices and public offering prices, the names of any agent, dealer or underwriter, and any applicable commissions or discounts with
respect to a particular offer will be set forth in an accompanying prospectus supplement or, if appropriate, a post-effective amendment to the registration statement that includes this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to comply with the securities laws of some states, if applicable, the common stock may be sold in these jurisdictions only through
registered or licensed brokers or dealers. In addition, in some states the common stock may not be sold unless it has been registered or qualified for sale or an exemption from registration or qualification requirements is available and is complied
with. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have advised the selling stockholders that the anti-manipulation rules of Regulation M under the Exchange Act may apply to sales
of shares in the market and to the activities of the selling stockholders and their affiliates. In addition, to the extent applicable, we will make copies of this prospectus (as it may be supplemented or amended from time to time) available to the
selling stockholders for the purpose of satisfying the prospectus delivery requirements of the Securities Act. The selling stockholders may indemnify any broker-dealer that participates in transactions involving the sale of the shares against
certain liabilities, including liabilities arising under the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have agreed to indemnify the selling stockholders against
liabilities, including liabilities under the Securities Act and state securities laws, relating to the registration of the shares of common stock offered by this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have agreed with the selling stockholders to use commercially reasonable efforts to cause
the registration statement of which this prospectus constitutes a part to become effective and to remain continuously effective until the earlier of: (i)&nbsp;the date on which the selling stockholders shall have resold or otherwise disposed of all
the shares covered by this prospectus, and (ii)&nbsp;the date on which the securities covered by this prospectus no longer constitute &#8220;Registrable Securities&#8221; as such term is defined in the Registration Rights Agreement, such that they
may be resold by the selling stockholders without registration and without regard to any volume or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">manner-of-sale</FONT></FONT> limitations and without current public information
pursuant to Rule 144 under the Securities Act or any other rule of similar effect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom108102_8"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cooley LLP will pass upon the validity of the shares of our common stock offered by this prospectus. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom108102_9"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The consolidated financial statements of Ovid Therapeutics Inc. and subsidiaries as of December&nbsp;31, 2025 and 2024, and for the years then
ended, have been incorporated by reference herein and in the registration statement in reliance upon the report of KPMG LLP, independent registered public accounting firm, incorporated by reference herein, and upon the authority of said firm as
experts in accounting and auditing. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom108102_10"></A>WHERE YOU CAN FIND ADDITIONAL INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus is part of the registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> we filed with the SEC under the
Securities Act and does not contain all of the information set forth in the registration statement. Whenever a reference is made in this prospectus to any of our contracts, agreements or other documents, the reference may not be complete and you
should refer to the exhibits that are a part of the registration statement or the exhibits to the reports or other documents incorporated by reference into this prospectus for a copy of such contract, agreement or other document. Because we are
subject to the information and reporting requirements of the Exchange Act, we file annual, quarterly and current reports, proxy statements and other information with the SEC. Our SEC filings are available to the public over the Internet at the
SEC&#8217;s website at http://www.sec.gov. We maintain a website at www.ovidrx.com. Information contained in or accessible through our website does not constitute a part of this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom108102_11"></A>INCORPORATION OF CERTAIN INFORMATION BY REFERENCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The SEC allows us to &#8220;incorporate by reference&#8221; information from other documents that we file with it, which means that we can
disclose important information to you by referring you to those documents. The information incorporated by reference is considered to be part of this prospectus. Information in this prospectus supersedes information incorporated by reference that we
filed with the SEC prior to the date of this prospectus, while information that we file later with the SEC will automatically update and supersede the information in this prospectus. We incorporate by reference into this prospectus and the
registration statement of which this prospectus is a part the information or documents listed below and any future filings made by us with the SEC (in each case, other than current reports or portions thereof furnished under Item 2.02 or Item 7.01
of Form <FONT STYLE="white-space:nowrap">8-K</FONT> and exhibits filed on such form that are related to such items and other portions of documents that are furnished, but not filed, or are otherwise not incorporated into registration statements
pursuant to applicable rules promulgated by the SEC) that are filed by us with the SEC pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act (i)&nbsp;after the date of the initial filing of the registration statement of which this
prospectus is a part and prior to effectiveness of the registration statement, and (ii)&nbsp;after the effectiveness of the registration statement but prior to the termination of the offering of the securities covered by this prospectus: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2025,
filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1636651/000162828026019438/ovid-20251231.htm">March<U></U>&nbsp;18, 2026</A>; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1636651/000162828026019045/ovid-20260318.htm">March
<U></U>&nbsp;18, 2026</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001636651/000162828026025926/ovid-20260420.htm">April 20, 2026</A>; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the description of our securities, which is contained in <A HREF="http://www.sec.gov/Archives/edgar/data/1636651/000162828026019438/ovid-fy202510xkxdescript.htm">Exhibit
 4.2</A> of our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2025, filed with the SEC on March&nbsp;18, 2026. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will provide to each person, including any beneficial owner, to whom a prospectus is delivered, without charge upon written or oral
request, a copy of any or all of the documents that are incorporated by reference into this prospectus but not delivered with the prospectus, including exhibits that are specifically incorporated by reference into such documents. You can request a
copy of these documents and filings, at no cost, by writing or telephoning us at the following address or telephone number: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Ovid
Therapeutics Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Attn: Corporate Secretary </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">441 Ninth Avenue, 14th Floor </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">New
York, NY 10001 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(646) <FONT STYLE="white-space:nowrap">661-7661</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with Rule 412 of the Securities Act, any statement contained in a document incorporated by reference herein shall be deemed
modified or superseded to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g108102g02a01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g108102g02a01.jpg
M_]C_X  02D9)1@ ! 0 #YP/G  #_[1HZ4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &AT
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 2(  A$! Q$!_\0 '    00# 0                (&!P@! P4$_\0 51
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MJMAP&_-=_P"[]JJA%@R!6PX#_FN[]W[5Y]WP7@2202$EP!.^=@MB%S2X@ D
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MSMC<"TM.<CJK!>C[JHSTTENJ7'#.1D0SG.<KZO8A'+#G$^.FG!TR=$("%SR
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M&3DI2@D$(1G= "$90@!""<)+G *&Z I"2'A*&_1$TP"$(4@$(0@!"$( 0A"
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M9P-I,]/4U2-Q=/\ $>YG^H?[E'GHPG-)=/VGV-6T7\ 3F:>,YRT?0E,C:S.
M/H2T96 .-JO\W[C^Q<H'X)X&L;A@]X31^]RGC5>!I^X^N%RKWPMK8;7J*ZU=
M0XX:]K^[UVYEZM>-XI LT78&78"290?D.;Z]U &H^(UZNU::*RQX82>\^/&/
MG&4WI-5:OLTO;U(B,0Z\H)^I9+&"T>1@>9\DDY!.=U'_  OUU'J>AC9,'"I
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M0 A"$ (/0H1X(!D\6_S(N0_J'J/?1C&*>Z?M/L:I"XMC^)-R_8/]RCWT8_\
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MZ?M/L:I#XM_F5<OV#_<H]]&,?P>Z8_G/L:ME_F">$(6!U*P!R-7?F[<?V+E
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M5FFBY@7OCV'SKJ\#P1IG;R;]JU?X DAWR7859==C_3/0_P#B(O\ J%69?N"
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MX+A6T)<'P0Q@,#M_,?8M6E-6O(+((0A>< A"$ (0A "$(0 A"$ (0A "$(0
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MP^27C/4IV,D;+$)&$.:1MA0%:."ESH;JR47&G-*QP(8.;I]"G.UTIHZ%D#I
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/%E"D"<;YSLLC"RA ?__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
